Drug Patents Expiring in 2025

1. Drug name - ABILIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method Jan, 2025

(2 years from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method Jan, 2025

(2 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
9.75MG/1.3ML (7.5MG/ML) INJECTABLE;INTRAMUSCULAR Discontinued

2. Drug name - ABILIFY MAINTENA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8399469 OTSUKA PHARM CO LTD Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338427 OTSUKA PHARM CO LTD Methods for administering aripiprazole Mar, 2025

(2 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Treatment of schizophrenia; use of aripiprazole in extended release injectable suspension in treating acute episodes of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
300MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
300MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
400MG FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

3. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820788

(Pediatric)

ABRAXIS BIOSCIENCE Compositions and methods of delivery of pharmacological agents Apr, 2025

(2 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

4. Drug name - ACETADOTE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof Aug, 2025

(2 years from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof Aug, 2025

(2 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6GM/30ML (200MG/ML) INJECTABLE;INTRAVENOUS Prescription

5. Drug name - ADRENACLICK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297136 IMPAX Medicine injection devices and methods Jan, 2025

(2 years from now)

US10166334 IMPAX Medicine injection apparatuses Jan, 2025

(2 years from now)

US7621891 IMPAX Method and apparatus for delivering epinephrine Feb, 2025

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.15MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Discontinued
EQ 0.3MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

6. Drug name - AEMCOLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741948 REDHILL Oral antimicrobial pharmaceutical compositions May, 2025

(2 years from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions May, 2025

(2 years from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions May, 2025

(2 years from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions May, 2025

(2 years from now)

Drugs and Companies using RIFAMYCIN SODIUM ingredient

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 194MG BASE TABLET, DELAYED RELEASE;ORAL Prescription

7. Drug name - AFINITOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410131 NOVARTIS Cancer treatment Nov, 2025

(3 years from now)

Drugs and Companies using EVEROLIMUS ingredient

Treatment: Treatment of solid excretory system tumors; advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

8. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament Mar, 2025

(2 years from now)

US9987229

(Pediatric)

TEVA PHARM Process for preparing a medicament Mar, 2025

(2 years from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus May, 2025

(2 years from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus May, 2025

(2 years from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus Nov, 2025

(3 years from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

9. Drug name - AKLIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors Dec, 2025

(3 years from now)

US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors Dec, 2025

(3 years from now)

Drugs and Companies using TRIFAROTENE ingredient

Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.005% CREAM;TOPICAL Prescription

10. Drug name - AMITIZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder Sep, 2025

(2 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome; method for the long term treatment of chronic constipation in a human subject

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MCG CAPSULE;ORAL Prescription
24MCG CAPSULE;ORAL Prescription

11. Drug name - AMONDYS 45

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9447415 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

Drugs and Companies using CASIMERSEN ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

12. Drug name - AMRIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7387793 TEVA PHARMS INTL Modified release dosage forms of skeletal muscle relaxants Feb, 2025

(2 years from now)

Drugs and Companies using CYCLOBENZAPRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
15MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
30MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

13. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

IN255064B GLAXOSMITHKLINE 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide
Apr, 2025

(2 years from now)

IN200605413P1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128A1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A4 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A2 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177B1 GLAXOSMITHKLINE Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists Jul, 2025

(2 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

14. Drug name - ANTARA (MICRONIZED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate Apr, 2025

(2 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Treating severe hypertriglyceridemia; treating primary hypercholesterolemia and mixed dyslipidemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE;ORAL Prescription
43MG CAPSULE;ORAL Prescription
87MG CAPSULE;ORAL Discontinued
90MG CAPSULE;ORAL Prescription
130MG CAPSULE;ORAL Prescription

15. Drug name - APTIOM

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702536 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US10695354 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

US10675287 SUNOVION PHARMS INC Methods of treatment of partial onset seizures using eslicarbazepine acetate May, 2025

(2 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; treatment of partial-onset seizures

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription
400MG TABLET;ORAL Prescription
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

16. Drug name - ARCAPTA NEOHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6878721 NOVARTIS Beta2-adrenoceptor agonists
Feb, 2025

(2 years from now)

Drugs and Companies using INDACATEROL MALEATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 75MCG BASE POWDER;INHALATION Discontinued

17. Drug name - ARIKAYCE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718189 INSMED INC Sustained release of antiinfectives Jun, 2025

(2 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 590MG BASE/8.4ML SUSPENSION, LIPOSOMAL;INHALATION Prescription

18. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9616024

(Pediatric)

TEVA PHARM Process for preparing a medicament Mar, 2025

(2 years from now)

US10765820 TEVA PHARM Dry powder inhalation apparatus May, 2025

(2 years from now)

US9463288 TEVA PHARM Dry powder inhalation apparatus May, 2025

(2 years from now)

US10765820

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus Nov, 2025

(3 years from now)

US9463288

(Pediatric)

TEVA PHARM Dry powder inhalation apparatus Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

19. Drug name - ASTEPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine Nov, 2025

(3 years from now)

US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof Nov, 2025

(3 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY SPRAY, METERED;NASAL Discontinued
0.2055MG/SPRAY SPRAY, METERED;NASAL Discontinued

20. Drug name - ASTEPRO ALLERGY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919050 BAYER HLTHCARE Compositions comprising azelastine Nov, 2025

(3 years from now)

US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof Nov, 2025

(3 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Treatment: Otc use: allergy symptom reliever; temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.2055MG/SPRAY SPRAY, METERED;NASAL Over the counter

21. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery Jan, 2025

(2 years from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery Mar, 2025

(2 years from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery Apr, 2025

(2 years from now)

US9149579 KALEO INC Devices, systems and methods for medicament delivery Jul, 2025

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Method of treating allergic reaction via injection

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

22. Drug name - BAXDELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(3 years from now)

EP3056492B1 MELINTA Meglumine Salt And Crystalline Forms Thereof Of A Drug (Delafloxacin)
Oct, 2025

(3 years from now)

EP3056492A1 MELINTA Meglumine Salt And Crystalline Forms Thereof Of A Drug (Delafloxacin)
Oct, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648093 MELINTA Salt and crystalline forms thereof of a drug Oct, 2025

(3 years from now)

US8969569 MELINTA Salt and crystalline forms thereof of a drug Oct, 2025

(3 years from now)

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

23. Drug name - BEPREVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784789 BAUSCH AND LOMB INC Aqueous liquid preparations and light-stabilized aqueous liquid preparations Jan, 2025

(2 years from now)

Drugs and Companies using BEPOTASTINE BESILATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
1.5% SOLUTION/DROPS;OPHTHALMIC Prescription

24. Drug name - BIKTARVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

EP1789139B1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE;120MG;EQ 15MG BASE TABLET;ORAL Prescription
EQ 50MG BASE;200MG;EQ 25MG BASE TABLET;ORAL Prescription

25. Drug name - BOSULIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Dec, 2025

(3 years from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) Dec, 2025

(3 years from now)

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Treatment: A method of treating chronic myelogenous leukemia

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE TABLET;ORAL Prescription
EQ 400MG BASE TABLET;ORAL Prescription
EQ 500MG BASE TABLET;ORAL Prescription

26. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7439393 GLAXO GRP LTD Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

27. Drug name - BRISDELLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598271 SEBELA IRELAND LTD Crystalline paroxetine methane sulfonate
May, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 7.5MG BASE CAPSULE;ORAL Prescription

28. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Dec, 2025

(3 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

29. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Dec, 2025

(3 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

30. Drug name - CABENUVA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

EP1789139B1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription
600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

31. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7717889 SAGE PRODS Disinfectant delivery system and method of providing alcohol free disinfection Feb, 2025

(2 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Treatment: For the preparation of skin prior to surgery; helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% CLOTH;TOPICAL Over the counter

32. Drug name - CIPRODEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846650 NOVARTIS Method of treating middle ear infections Jun, 2025

(2 years from now)

Drugs and Companies using CIPROFLOXACIN; DEXAMETHASONE ingredient

Treatment: Treatment of acute otitis media

Dosage: SUSPENSION/DROPS;OTIC

More Information on Dosage
Strength Dosage Availability
0.3%;0.1% SUSPENSION/DROPS;OTIC Prescription

33. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function May, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

34. Drug name - COMPLERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

EP1789139B1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841310 GILEAD SCIENCES INC Combinations of a pyrimidine containing NNRTI with RT inhibitors Dec, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;300MG TABLET;ORAL Prescription

35. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7375111 NALPROPION Compositions for affecting weight loss Mar, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

36. Drug name - COREG CR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101209 WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles Sep, 2025

(2 years from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
20MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
40MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
80MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

37. Drug name - CRESEMBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6812238 ASTELLAS N-substituted carbamoyloxyalkyl-azolium derivatives
Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
372MG POWDER;INTRAVENOUS Prescription

38. Drug name - DAYTRANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers Oct, 2025

(3 years from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers Oct, 2025

(3 years from now)

US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers Oct, 2025

(3 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
10MG/9HR (1.1MG/HR) FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
15MG/9HR (1.6MG/HR) FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
20MG/9HR (2.2MG/HR) FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
30MG/9HR (3.3MG/HR) FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

39. Drug name - DESCOVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

EP1789139B1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
120MG;EQ 15MG BASE TABLET;ORAL Prescription
200MG;EQ 25MG BASE TABLET;ORAL Prescription

40. Drug name - DIFFERIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7579377 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Feb, 2025

(2 years from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3% GEL;TOPICAL Prescription

41. Drug name - DIPRIVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures Jun, 2025

(2 years from now)

Drugs and Companies using PROPOFOL ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
10MG/ML INJECTABLE;INJECTION Prescription

42. Drug name - DOJOLVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186344 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method Jul, 2025

(2 years from now)

US8697748 ULTRAGENYX PHARM INC Glycogen or polysaccharide storage disease treatment method Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
100% w/w LIQUID;ORAL Prescription

43. Drug name - DOPTELET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7638536 AKARX INC 2-Acylaminothiazole derivative or salt thereof
May, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription

44. Drug name - DUAKLIR PRESSAIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46417 ASTRAZENECA Quinuclidine derivatives and their use as muscarinic M3 receptor ligands
Feb, 2025

(2 years from now)

EP1200431BA ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptor Ligands
Jul, 2025

(2 years from now)

EP1200431A2 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands
Jul, 2025

(2 years from now)

EP1200431B3 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands
Jul, 2025

(2 years from now)

EP1200431B1 ASTRAZENECA Quinuclidine Derivatives And Their Use As Muscarinic M3 Receptors Ligands
Jul, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
0.4MG/INH;0.012MG/INH POWDER, METERED;INHALATION Prescription

45. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants Feb, 2025

(2 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

46. Drug name - DUZALLO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(2 years from now)

CN101817793A IRONWOOD PHARMS INC S-Triazolyl A-Mercaptoacet Anilides As Hiv Reverse Transcriptase Inhibitor
Aug, 2025

(2 years from now)

CN101083987A IRONWOOD PHARMS INC S - Triazolyl A - Hydrosulphonyl Acetanilide As Hiv Revertase Inhibitor
Aug, 2025

(2 years from now)

CN101817793B IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

CN101083987B IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

IN262812B IRONWOOD PHARMS INC 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio)Acetic Acid, Methyl Ester, And 2-Chloro-4-Sulfamoylphenyl Amide
Aug, 2025

(2 years from now)

IN200701232P4 IRONWOOD PHARMS INC 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio)Acetic Acid And Methyl Ester
Aug, 2025

(2 years from now)

EP2402011B1 IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP1789039B1 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2402011A1 IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP1789039A4 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP1789039A2 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2135608B8 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2135608B1 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2135608A1 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;200MG TABLET;ORAL Discontinued
300MG;200MG TABLET;ORAL Discontinued

47. Drug name - EDARBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 ARBOR PHARMS LLC Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

CN100503605C ARBOR PHARMS LLC Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists
Feb, 2025

(2 years from now)

CN101381366B ARBOR PHARMS LLC Benzimidazole Derivatives And Their Pharmaceutical Use
Feb, 2025

(2 years from now)

CN101381366A ARBOR PHARMS LLC Benzimidazole Derivative And Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

CN1946717A ARBOR PHARMS LLC Benzimidazole Derivative And Its Use
Feb, 2025

(2 years from now)

IN242537B ARBOR PHARMS LLC Benzimidazole Derivative And A Process For The Preparation Thereof
Feb, 2025

(2 years from now)

IN200602785P2 ARBOR PHARMS LLC Benzimidazole Derivative And Use Thereof
Feb, 2025

(2 years from now)

EP2119715B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP2119715A1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A2 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A3 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 ARBOR PHARMS LLC Benzimidazole derivative and use as a II receptor antagonist Jan, 2025

(2 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL TABLET;ORAL Prescription
EQ 80MG MEDOXOMIL TABLET;ORAL Prescription

48. Drug name - EDARBYCLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 ARBOR PHARMS LLC Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

CN100503605C ARBOR PHARMS LLC Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists
Feb, 2025

(2 years from now)

CN101381366B ARBOR PHARMS LLC Benzimidazole Derivatives And Their Pharmaceutical Use
Feb, 2025

(2 years from now)

CN101381366A ARBOR PHARMS LLC Benzimidazole Derivative And Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

CN1946717A ARBOR PHARMS LLC Benzimidazole Derivative And Its Use
Feb, 2025

(2 years from now)

IN242537B ARBOR PHARMS LLC Benzimidazole Derivative And A Process For The Preparation Thereof
Feb, 2025

(2 years from now)

IN200602785P2 ARBOR PHARMS LLC Benzimidazole Derivative And Use Thereof
Feb, 2025

(2 years from now)

EP2119715B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP2119715A1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A2 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A3 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 ARBOR PHARMS LLC Benzimidazole derivative and use as a II receptor antagonist Jan, 2025

(2 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL;12.5MG TABLET;ORAL Prescription
EQ 40MG MEDOXOMIL;25MG TABLET;ORAL Prescription

49. Drug name - EDURANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7125879 JANSSEN PRODS HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

EP1789139B1 JANSSEN PRODS Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 JANSSEN PRODS Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription

50. Drug name - EMBEDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685444 ALPHARMA PHARMS Sequestering subunit and related compositions and methods Jul, 2025

(2 years from now)

US8685443 ALPHARMA PHARMS Sequestering subunit and related compositions and methods Jul, 2025

(2 years from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG;0.8MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
30MG;1.2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
50MG;2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
60MG;2.4MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
80MG;3.2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
100MG;4MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued

51. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101659 NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jan, 2025

(2 years from now)

US8101659

(Pediatric)

NOVARTIS PHARMS CORP Methods of treatment and pharmaceutical composition Jul, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

52. Drug name - EPANOVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form Feb, 2025

(2 years from now)

US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form Feb, 2025

(2 years from now)

US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form Feb, 2025

(2 years from now)

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

Treatment: Treatment of hypertriglyceridemia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS CAPSULE;ORAL Discontinued

53. Drug name - EPI E Z PEN JR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover Sep, 2025

(2 years from now)

US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover Sep, 2025

(2 years from now)

US7449012 MYLAN SPECIALITY LP Automatic injector Sep, 2025

(2 years from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation Sep, 2025

(2 years from now)

US8870827 MYLAN SPECIALITY LP Automatic injector Sep, 2025

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.15MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Prescription
0.3MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Prescription

54. Drug name - EPIDUO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
0.1%;2.5% GEL;TOPICAL Prescription

55. Drug name - ERIVEDGE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling Sep, 2025

(2 years from now)

Drugs and Companies using VISMODEGIB ingredient

Treatment: Method of using vismodegib to treat basal cell carcinoma

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG CAPSULE;ORAL Prescription

56. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery Jan, 2025

(2 years from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery Mar, 2025

(2 years from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery Apr, 2025

(2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

57. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7731690 KALEO INC Devices, systems and methods for medicament delivery Jan, 2025

(2 years from now)

US8016788 KALEO INC Devices, systems and methods for medicament delivery Mar, 2025

(2 years from now)

US10335549 KALEO INC Devices, systems and methods for medicament delivery Apr, 2025

(2 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

58. Drug name - EXONDYS 51

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by inducing skipping of exon 51; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by correcting a defective gene for dystrophin; treatment of duchenne muscular dystrophy (dmd) in patients having a mutation of the dmd gene that is amenable to exon 51 skipping by restoring or increasing functional dystrophin protein production

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

59. Drug name - FANAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138432 VANDA PHARMS INC Methods for the administration of iloperidone Sep, 2025

(3 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

60. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

61. Drug name - FEMTRACE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572779 APIL Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation Oct, 2025

(3 years from now)

Drugs and Companies using ESTRADIOL ACETATE ingredient

Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.45MG TABLET;ORAL Discontinued
0.9MG TABLET;ORAL Discontinued
1.8MG TABLET;ORAL Discontinued

62. Drug name - FOLOTYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622470 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin May, 2025

(2 years from now)

US8299078 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin May, 2025

(2 years from now)

Drugs and Companies using PRALATREXATE ingredient

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
20MG/ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
40MG/2ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

63. Drug name - FORTEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7517334 LILLY Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose Mar, 2025

(2 years from now)

Drugs and Companies using TERIPARATIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.6MG/2.4ML (0.25MG/ML) SOLUTION;SUBCUTANEOUS Prescription
0.75MG/3ML (0.25MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

64. Drug name - GATTEX KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9545434 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9060992 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9993528 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9545435 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9968658 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9987334 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9968655 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9555079 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9981016 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9974835 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9539310 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9592273 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9968656 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9987335 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9592274 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9974837 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9981014 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US9572867 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

US7847061 NPS PHARMS INC Treatment of short bowel syndrome patients with colon-in-continuity Nov, 2025

(3 years from now)

Drugs and Companies using TEDUGLUTIDE RECOMBINANT ingredient

Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
5MG/VIAL POWDER;SUBCUTANEOUS Prescription

65. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609028 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Aug, 2025

(2 years from now)

US9522249 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Aug, 2025

(2 years from now)

US8821801 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Aug, 2025

(2 years from now)

US9956373 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Aug, 2025

(2 years from now)

US8226916 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Aug, 2025

(2 years from now)

US10124142 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Aug, 2025

(2 years from now)

US10814092 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Oct, 2025

(3 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

66. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

EP1789139B1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

67. Drug name - GIVLAARI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(2 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

68. Drug name - GLUMETZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7780987 SANTARUS INC Controlled release dosage forms
Mar, 2025

(2 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET, EXTENDED RELEASE;ORAL Prescription
500MG TABLET, EXTENDED RELEASE;ORAL Prescription

69. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

70. Drug name - GOCOVRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895615 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895616 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8796337 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895617 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895618 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895614 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8889740 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 68.5MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription
EQ 137MG BASE CAPSULE, EXTENDED RELEASE;ORAL Prescription

71. Drug name - HORIZANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6818787 ARBOR PHARMS LLC Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034 ARBOR PHARMS LLC Crystalline form of γ-aminobutyric acid analog Jan, 2025

(2 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

72. Drug name - INCIVEK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820671 VERTEX PHARMS Peptidomimetic protease inhibitors
Feb, 2025

(2 years from now)

Drugs and Companies using TELAPREVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
375MG TABLET;ORAL Discontinued

73. Drug name - INCRUSE ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498440 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

IN255064B GLAXO GRP ENGLAND 4-[Hydroxy(Diphenyl)Methyl]-1-(2-[(Phenylmethyl)Oxy]Ethyl}-1-Azoniabicyclo[2.2.2.]Octane Bromide
Apr, 2025

(2 years from now)

IN200605413P1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128A1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP2570128B1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A4 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177A2 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

EP1740177B1 GLAXO GRP ENGLAND Muscarinic Acetylcholine Receptor Antagonists
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists Apr, 2025

(2 years from now)

US8183257 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists Jul, 2025

(2 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 62.5MCG BASE/INH POWDER;INHALATION Prescription

74. Drug name - INLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6534524 PF PRISM CV Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Apr, 2025

(2 years from now)

EP1218348B1 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2025

(2 years from now)

EP1218348A2 PF PRISM CV Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use
Jun, 2025

(2 years from now)

Drugs and Companies using AXITINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription

75. Drug name - INTERMEZZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682628 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof Feb, 2025

(2 years from now)

US8252809 PURDUE PHARMA Compositions for treating insomnia Feb, 2025

(2 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method for treating insomnia

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
1.75MG TABLET;SUBLINGUAL Discontinued
3.5MG TABLET;SUBLINGUAL Discontinued

76. Drug name - INVOKAMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;500MG TABLET;ORAL Prescription
50MG;1GM TABLET;ORAL Prescription
150MG;500MG TABLET;ORAL Prescription
150MG;1GM TABLET;ORAL Prescription

77. Drug name - INVOKAMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
50MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

78. Drug name - INVOKANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound Apr, 2025

(2 years from now)

Drugs and Companies using CANAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

79. Drug name - IXEMPRA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7312237

(Pediatric)

R-PHARM US LLC Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases Feb, 2025

(2 years from now)

Drugs and Companies using IXABEPILONE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
15MG/VIAL INJECTABLE;INTRAVENOUS Prescription
45MG/VIAL INJECTABLE;INTRAVENOUS Prescription

80. Drug name - JENTADUETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
2.5MG;850MG TABLET;ORAL Prescription

81. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines Nov, 2025

(3 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

82. Drug name - JEVTANA KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7241907 SANOFI AVENTIS US Acetone solvate of dimethoxy docetaxel and its process of preparation
Dec, 2025

(3 years from now)

Drugs and Companies using CABAZITAXEL ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
60MG/1.5ML (40MG/ML) SOLUTION;INTRAVENOUS Prescription

83. Drug name - JULUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

EP1789139B1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 VIIV HLTHCARE Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

84. Drug name - JUXTAPID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433617 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US9265758 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US9364470 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US10016404 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Mar, 2025

(2 years from now)

US10555938 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Mar, 2025

(2 years from now)

US9861622 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects Mar, 2025

(2 years from now)

US8618135 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Mar, 2025

(2 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 30MG BASE CAPSULE;ORAL Prescription
EQ 40MG BASE CAPSULE;ORAL Discontinued
EQ 60MG BASE CAPSULE;ORAL Discontinued

85. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

86. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Treatment of a moderate mild clinical phenotype of cf using ivacaftor in a patient age 6 months to <6 years who has one cftr mutation repsonsive to ivacaftor based on clinical and/or in vitro assay data; use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

87. Drug name - KAZANO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Mar, 2025

(2 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;1GM TABLET;ORAL Prescription
EQ 12.5MG BASE;500MG TABLET;ORAL Prescription

88. Drug name - KLISYRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(3 years from now)

US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(3 years from now)

CN103274961B ALMIRALL Compounds And Methods For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN101184734B ALMIRALL Compounds And Methods For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN101184734A ALMIRALL Compound And Method For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN103274961A ALMIRALL Compounds And Methods For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN200702504P2 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN201400549P2 ALMIRALL Compounds For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN259746B ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN339823B ALMIRALL Compounds For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP1836169A2 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP1836169B9 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP1836169B1 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

89. Drug name - KOMBIGLYZE XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339472 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

US8628799 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

90. Drug name - KUVAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7727987

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride May, 2025

(2 years from now)

USRE43797

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin May, 2025

(2 years from now)

US8318745

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride May, 2025

(2 years from now)

US7566714

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders May, 2025

(2 years from now)

US8067416

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders May, 2025

(2 years from now)

US7612073

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring May, 2025

(2 years from now)

US8003126 BIOMARIN PHARM Stable tablet formulation Nov, 2025

(3 years from now)

US7566462 BIOMARIN PHARM Stable tablet formulation Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription

91. Drug name - KYBELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846066 KYTHERA BIOPHARMS Methods and related compositions for reduction of fat and skin tightening Feb, 2025

(2 years from now)

US8298556 KYTHERA BIOPHARMS Methods and related compositions for the non-surgical removal of fat Aug, 2025

(2 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Treatment: Method for reduction of submental fat

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
20MG/2ML (10MG/ML) SOLUTION;SUBCUTANEOUS Prescription

92. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8207297 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(2 years from now)

US7232818 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(2 years from now)

US8207125 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(2 years from now)

CN101044157A ONYX THERAP Compound For Inhabiting Proteasome
Apr, 2025

(2 years from now)

CN101044157B ONYX THERAP Compound For Proteasome Inhibition
Apr, 2025

(2 years from now)

CN101006098A ONYX THERAP Compound For Inhibiting Proteasome Enzyme
Apr, 2025

(2 years from now)

CN102286070A ONYX THERAP Compound For Proteasome Inhibition
Apr, 2025

(2 years from now)

CN102286070B ONYX THERAP Compound For Proteasome Inhibition
Apr, 2025

(2 years from now)

CN101006098B ONYX THERAP Compound For Inhibiting Proteasome Enzyme
Apr, 2025

(2 years from now)

IN255964B ONYX THERAP Compounds For Enzyme Inhibition
Apr, 2025

(2 years from now)

IN200605644P1 ONYX THERAP Compounds For Enzyme Inhibition
Apr, 2025

(2 years from now)

EP1745064A2 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Apr, 2025

(2 years from now)

EP1745064B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Apr, 2025

(2 years from now)

EP3101026A1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2270026B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2266999B1 ONYX THERAP Compounds For Proteasome Enzym Inhibition
Aug, 2025

(2 years from now)

EP2266999A3 ONYX THERAP Compounds For Proteasome Enzym Inhibition
Aug, 2025

(2 years from now)

EP2266999A2 ONYX THERAP Compounds For Proteasome Enzym Inhibition
Aug, 2025

(2 years from now)

EP2270026A3 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP3101026B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP2270026A2 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP1781688B1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

EP1781688A1 ONYX THERAP Compounds For Proteasome Enzyme Inhibition
Aug, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8129346 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US8207127 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US7491704 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

US8207126 ONYX THERAP Compounds for enzyme inhibition Apr, 2025

(2 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: Kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

93. Drug name - LATUDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE45573 SUNOVION PHARMS INC Process for producing imide compound
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE45573

(Pediatric)

SUNOVION PHARMS INC Process for producing imide compound Dec, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription
60MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription
120MG TABLET;ORAL Prescription

94. Drug name - LENVIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription

95. Drug name - LOCOID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7981877 BAUSCH Stabilized steroid composition and method for its preparation Jan, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
0.1% LOTION;TOPICAL Prescription

96. Drug name - LONHALA MAGNAIR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7931212 SUNOVION RESP Fluid droplet production apparatus and method Nov, 2025

(3 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage
Strength Dosage Availability
25MCG/ML SOLUTION;INHALATION Prescription

97. Drug name - LUMIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524777 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8586630 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8309605 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8299118 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933120 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8933127 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9241918 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8278353 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8772338 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US8338479 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

US9155716 ALLERGAN Enhanced bimatoprost ophthalmic solution Mar, 2025

(2 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension; A method of reducing intraocular pressure in patients with open angle glaucoma or ocular hypertension; A method of lowering intraocular pressure in a patient with open angle glaucoma or ocular hypertension; method of treating glaucoma in a patient; A method of treating a patient with glaucoma or ocular hypertension; Method of treating glaucoma or elevated intraocular pressure; A method of lowering intraocular pressure

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.01% SOLUTION/DROPS;OPHTHALMIC Prescription

98. Drug name - LYBALVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7262298 ALKERMES INC 4-hydroxybenzomorphans
Nov, 2025

(3 years from now)

CN101090891A ALKERMES INC 4-Hydroxyl Benzomorphan
Nov, 2025

(3 years from now)

CN101090891B ALKERMES INC 4 Benzomorphan
Nov, 2025

(3 years from now)

IN200701789P2 ALKERMES INC 4-Hydroxybenzomorphans
Nov, 2025

(3 years from now)

IN257106B ALKERMES INC Novel Compounds (4-Hydroxybenzomorphans) As Analgesics, Antipruritics, Antidirrheal Agents
Nov, 2025

(3 years from now)

EP2251330A1 ALKERMES INC 4-Hydroxybenzomorphans
Nov, 2025

(3 years from now)

EP2251330B1 ALKERMES INC 4-Hydroxybenzomorphans
Nov, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
5MG;EQ 10MG BASE TABLET;ORAL Prescription
10MG;EQ 10MG BASE TABLET;ORAL Prescription
15MG;EQ 10MG BASE TABLET;ORAL Prescription
20MG;EQ 10MG BASE TABLET;ORAL Prescription

99. Drug name - LYMPHOSEEK KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6409990 CARDINAL HEALTH 414 Macromolecular carrier for drug and diagnostic agent delivery
May, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
N/A INJECTABLE;INJECTION Prescription

100. Drug name - LYSTEDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022106 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US7947739 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US9060939 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US8809394 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US8957113 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US8791160 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US8487005 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

US8273795 AMRING PHARMS Tranexamic acid formulations Mar, 2025

(2 years from now)

Drugs and Companies using TRANEXAMIC ACID ingredient

Treatment: Treatment of cyclic heavy menstrual bleeding

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
650MG TABLET;ORAL Prescription

101. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835443 NOVARTIS Pyrimidine compound and medical use thereof Jun, 2025

(2 years from now)

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Treatment: Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; treatment of unresectable or metastatic melanoma; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; in combination with dabrafenib for the treatment of unresectable or metastatic melanoma.; mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

102. Drug name - MIRVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis May, 2025

(2 years from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May, 2025

(2 years from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema May, 2025

(2 years from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea Aug, 2025

(2 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 0.33% BASE GEL;TOPICAL Prescription

103. Drug name - NAMZARIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338486 ALLERGAN Methods for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

104. Drug name - NAROPIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7828787 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
1GM/200ML (5MG/ML) SOLUTION;INJECTION Prescription
50MG/10ML (5MG/ML) SOLUTION;INJECTION Discontinued
20MG/10ML (2MG/ML) SOLUTION;INJECTION Prescription
40MG/20ML (2MG/ML) SOLUTION;INJECTION Prescription
75MG/10ML (7.5MG/ML) SOLUTION;INJECTION Discontinued
100MG/20ML (5MG/ML) SOLUTION;INJECTION Prescription
100MG/10ML (10MG/ML) SOLUTION;INJECTION Prescription
150MG/20ML (7.5MG/ML) SOLUTION;INJECTION Prescription
150MG/30ML (5MG/ML) SOLUTION;INJECTION Prescription
200MG/100ML (2MG/ML) SOLUTION;INJECTION Prescription
200MG/20ML (10MG/ML) SOLUTION;INJECTION Prescription
400MG/200ML (2MG/ML) SOLUTION;INJECTION Prescription
500MG/100ML (5MG/ML) SOLUTION;INJECTION Prescription

105. Drug name - NERLYNX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982043 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors Oct, 2025

(3 years from now)

Drugs and Companies using NERATINIB MALEATE ingredient

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting; extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE TABLET;ORAL Prescription

106. Drug name - NESINA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Dec, 2025

(3 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 6.25MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

107. Drug name - NEUPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246980 UCB INC Transdermal delivery system Nov, 2025

(3 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

108. Drug name - NEVANAC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071648 NOVARTIS Topical nepafenac formulations Dec, 2025

(3 years from now)

US8324281 NOVARTIS Topical nepafenac formulations Dec, 2025

(3 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SUSPENSION/DROPS;OPHTHALMIC Prescription

109. Drug name - NEXLETOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
180MG TABLET;ORAL Prescription

110. Drug name - NEXLIZET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7335799 ESPERION THERAPS INC Hydroxyl compounds and compositions for cholesterol management and related uses
Dec, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
180MG;10MG TABLET;ORAL Prescription

111. Drug name - NEXTSTELLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception Mar, 2025

(2 years from now)

Drugs and Companies using DROSPIRENONE; ESTETROL ingredient

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG;14.2MG TABLET;ORAL Prescription

112. Drug name - NUCYNTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

CN1997621A COLLEGIUM PHARM INC Crystalline Form Of (-)-(1R, 2R)-3-(3-Dimethylamino-1-Ethide-2-Methyl Propyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

CN1997621B COLLEGIUM PHARM INC (-)-(1R, 2R) -3-(3-Dimethylamino - -1 - Ethyl -2 - Methyl Propyl) - Phenol Hydrochloride Of Crystalline Form
Jun, 2025

(2 years from now)

IN200603453P2 COLLEGIUM PHARM INC Crystalline Forms Of (−)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

IN242353B COLLEGIUM PHARM INC Crystalline Forms Of (-) -(1R, 2R) -3-(3-Dime Thylamino-1- Ethyl -2 Methyl Propyl ) -Phenol Hydrochlo Ride
Jun, 2025

(2 years from now)

EP1799633A2 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

EP1799633B1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/ML SOLUTION;ORAL Discontinued

113. Drug name - NUCYNTA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(2 years from now)

CN1997621A COLLEGIUM PHARM INC Crystalline Form Of (-)-(1R, 2R)-3-(3-Dimethylamino-1-Ethide-2-Methyl Propyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

CN1997621B COLLEGIUM PHARM INC (-)-(1R, 2R) -3-(3-Dimethylamino - -1 - Ethyl -2 - Methyl Propyl) - Phenol Hydrochloride Of Crystalline Form
Jun, 2025

(2 years from now)

IN200603453P2 COLLEGIUM PHARM INC Crystalline Forms Of (−)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride
Jun, 2025

(2 years from now)

IN242353B COLLEGIUM PHARM INC Crystalline Forms Of (-) -(1R, 2R) -3-(3-Dime Thylamino-1- Ethyl -2 Methyl Propyl ) -Phenol Hydrochlo Ride
Jun, 2025

(2 years from now)

EP1799633A2 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

EP1799633B1 COLLEGIUM PHARM INC Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions
Jun, 2025

(2 years from now)

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 150MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 200MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 250MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

114. Drug name - NULIBRY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7504095 ORIGIN Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency Jan, 2025

(2 years from now)

Drugs and Companies using FOSDENOPTERIN HYDROBROMIDE ingredient

Treatment: Method of treating molybdenum cofactor deficiency type a

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 9.5MG BASE/VIAL POWDER;INTRAVENOUS Prescription

115. Drug name - NUPLAZID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7923564 ACADIA PHARMS INC Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Sep, 2025

(2 years from now)

CN101035759A ACADIA PHARMS INC N-(4-Fluorobenzyl)-N-(1-Methyl Piperidine-4-Radical)-N'-(Methyl Propoxy) Phenyl Methyl) Carbamide, Synthesis And Crystalline Form Of Its Tartrate
Sep, 2025

(2 years from now)

CN101035759B ACADIA PHARMS INC N - (4) -N-(1 -4) -N '-(4 - (2) Phenylmethyl) Urine And Synthesis And Crystalline Form Of Tartrate
Sep, 2025

(2 years from now)

CN102153505B ACADIA PHARMS INC N - (4) -N-(1 -4) -N '-(4 - (2) Phenylmethyl) Carbamide And Its Synthesis And Crystalline Form Of The Tartrate
Sep, 2025

(2 years from now)

CN102153505A ACADIA PHARMS INC N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl) Carbamide, Synthetization Of Tartrate And Crystalline Form
Sep, 2025

(2 years from now)

CN101031548A ACADIA PHARMS INC Salt Of N-(4-Fluorobenzyl)-N-(1-Methyl Piperidine-4-Yl)-N'-(4-(2-Methyl Propyloxy)-Phenyl Methyl) Carbamide And Its Preparation
Sep, 2025

(2 years from now)

CN101031548B ACADIA PHARMS INC Salts Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy) Phenylmethyl) Carbamide And Their Preparation
Sep, 2025

(2 years from now)

IN265372B ACADIA PHARMS INC Synthesis Of N- (Fluorobenzyl)-N- (Methylpiperidin-4- Yl)-N'-(4-(2 Methylpropyloxy) Phenylmethyl) Carbamide And Its Tartrate Salt And Crystalline Forms
Sep, 2025

(2 years from now)

IN200701144P2 ACADIA PHARMS INC Synthesis Of N-(Fluorobenzyl)-N-(Methylpiperidin-4-Yl)-N'-(4-(2 Methylpropyloxy) Phenylmethyl) Carbamide And Its Tartrate Salt And Crystalline Forms
Sep, 2025

(2 years from now)

EP1794126B1 ACADIA PHARMS INC Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Hemi-Tartrate
Sep, 2025

(2 years from now)

EP2289879A1 ACADIA PHARMS INC Synthesis Of A Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Tartrate Salt
Sep, 2025

(2 years from now)

EP1794126A1 ACADIA PHARMS INC Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Hemi-Tartrate
Sep, 2025

(2 years from now)

EP2289879B1 ACADIA PHARMS INC Synthesis Of A Crystalline Form Of N-(4-Fluorobenzyl)-N-(1-Methylpiperidin-4-Yl)-N'-(4-(2-Methylpropyloxy)Phenylmethyl)Carbamide Tartrate Salt
Sep, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 34MG BASE CAPSULE;ORAL Prescription

116. Drug name - ODEFSEY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(2 years from now)

US7125879 GILEAD SCIENCES INC HIV inhibiting pyrimidines derivatives
Apr, 2025

(2 years from now)

EP1789139B1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

EP1789139A1 GILEAD SCIENCES INC Fumarate Of 4-((4-((4-(2-Cyanoethenyl)-2,6-Dimethylphenyl Amino -2-Pyrimidinyl Amino Benzonitrile
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues Oct, 2025

(3 years from now)

More Information on Dosage
Strength Dosage Availability
200MG;EQ 25MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

117. Drug name - OFEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases Dec, 2025

(3 years from now)

Drugs and Companies using NINTEDANIB ESYLATE ingredient

Treatment: Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild)

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 100MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

118. Drug name - OLUX E

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000 MYLAN Microemulsion and sub-micron emulsion process and compositions Aug, 2025

(2 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% AEROSOL, FOAM;TOPICAL Prescription

119. Drug name - OLYSIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7671032 JANSSEN PRODS HCV NS-3 serine protease inhibitors
May, 2025

(2 years from now)

IN256631B JANSSEN PRODS Cyclopentanyl Containing Macrocyclic Hcv Ns-3 Protease Inhibitors
Jan, 2025

(2 years from now)

IN200603860P1 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2025

(2 years from now)

EP1713822A2 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2025

(2 years from now)

EP1713822B1 JANSSEN PRODS Hcv Ns-3 Serine Protease Inhibitors
Jan, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE CAPSULE;ORAL Discontinued

120. Drug name - OMEGAVEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN) Jul, 2025

(2 years from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN) Jul, 2025

(2 years from now)

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

Treatment: Use for patients with parenteral nutrition associated cholestasis or parenteral nutrition associated liver disease; Treatment of liver disease through nutrition for patients under the age of 12

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
5GM/50ML (0.1GM/ML) EMULSION;INTRAVENOUS Prescription
10GM/100ML (0.1GM/ML) EMULSION;INTRAVENOUS Prescription

121. Drug name - OMEPRAZOLE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023391 DEXCEL PHARMA Stable benzimidazole formulation Aug, 2025

(2 years from now)

Drugs and Companies using OMEPRAZOLE ingredient

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, DELAYED RELEASE;ORAL Over the counter

122. Drug name - ONIVYDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8992970 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US9782349 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US10722508 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

US9724303 IPSEN INC Liposomes useful for drug delivery
May, 2025

(2 years from now)

CN103948545B IPSEN INC Liposome For Drug Delivery
May, 2025

(2 years from now)

CN1980637A IPSEN INC Lipidosome For Carrying The Medicine
May, 2025

(2 years from now)

CN107811971B IPSEN INC Liposomes For Drug Delivery
May, 2025

(2 years from now)

CN1980637B IPSEN INC Liposome For Drug Delivery
May, 2025

(2 years from now)

CN107811971A IPSEN INC A Medicine Conveying Liposome
May, 2025

(2 years from now)

CN103948545A IPSEN INC Liposome For Drug Delivery
May, 2025

(2 years from now)

IN201207908P1 IPSEN INC A Fluid Pharmaceutical Formulation
May, 2025

(2 years from now)

IN361032B IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

IN200607275P1 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

IN374803B IPSEN INC A Fluid Pharmaceutical Formulation
May, 2025

(2 years from now)

EP1746976A4 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

EP1746976A1 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

EP1746976B1 IPSEN INC Liposomes Useful For Drug Delivery
May, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703181 IPSEN INC Liposomes useful for drug delivery May, 2025

(2 years from now)

US9730891 IPSEN INC Liposomes useful for drug delivery May, 2025

(2 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: Treatment of pancreatic cancer; Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL;INTRAVENOUS Prescription

123. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334373 ALNYLAM PHARMS INC Nuclease resistant double-stranded ribonucleic acid
May, 2025

(2 years from now)

EP2399924A2 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2399924B1 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

EP2399924A3 ALNYLAM PHARMS INC Nuclease Resistant Double-Stranded Ribonucleic Acid
May, 2025

(2 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

124. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7975690 CURRAX Nasal devices Aug, 2025

(2 years from now)

US8590530 CURRAX Nasal delivery devices Sep, 2025

(2 years from now)

US9108015 CURRAX Nasal delivery devices Sep, 2025

(2 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Method of drug delivery via the nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

125. Drug name - OPANA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192722 ENDO PHARMS Abuse-proof dosage form Sep, 2025

(2 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

126. Drug name - OPSUMIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(3 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

127. Drug name - ORACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206740 GALDERMA LABS LP Once daily formulations of tetracyclines Dec, 2025

(3 years from now)

Drugs and Companies using DOXYCYCLINE ingredient

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription

128. Drug name - ORAVERSE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7575757 SEPTODONT HOLDING Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof Apr, 2025

(2 years from now)

Drugs and Companies using PHENTOLAMINE MESYLATE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
0.4MG/1.7ML INJECTABLE;INJECTION Prescription

129. Drug name - OSENI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors Mar, 2025

(2 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 12.5MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 12.5MG BASE;EQ 45MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 15MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 30MG BASE TABLET;ORAL Prescription
EQ 25MG BASE;EQ 45MG BASE TABLET;ORAL Prescription

130. Drug name - OSMOLEX ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072697 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8796337 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895617 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895618 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895614 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8987333 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895616 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8895615 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8889740 ADAMAS PHARMA Composition and method for treating neurological disease Nov, 2025

(3 years from now)

US8574626 ADAMAS PHARMA Osmotic device containing amantadine and an osmotic salt Nov, 2025

(3 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of parkinson's disease; treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; Treatment of parkinson's disease; treatment of drug-induced extrapyramidal reactions in adult patients with parkinson's disease; treatment of drug-induced extrapyramidal reaction in adult patients; A process for treating a patient suffering from parkinson's syndrome and in need of treatment

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 129MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 161MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
EQ 193MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 258MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

131. Drug name - OSPHENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6245819 DUCHESNAY Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause Jul, 2025

(2 years from now)

Drugs and Companies using OSPEMIFENE ingredient

Treatment: Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause; treatment of dyspareunia associated with menopause

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

132. Drug name - OXAYDO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7201920 ZYLA Methods and compositions for deterring abuse of opioid containing dosage forms Mar, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
7.5MG TABLET;ORAL Prescription

133. Drug name - OXYCONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(2 years from now)

US10407434 PURDUE PHARMA LP Process for preparing oxycodone compositions
Mar, 2025

(2 years from now)

US10696684 PURDUE PHARMA LP Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(2 years from now)

CN101812065B PURDUE PHARMA LP Contains Less Than 25 Ppm Ppm Of 14-Hydroxymethyl Codeine To Oxycodone Hydrochloride Ketone Can Be Ketone
Mar, 2025

(2 years from now)

CN1960994A PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102838607B PURDUE PHARMA LP Preparation Contains Less Than 25 Ppm Of 14-Hydroxide Can Be Oxycodone Method By Hydrochloric Acid
Mar, 2025

(2 years from now)

CN1960994B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN101812065A PURDUE PHARMA LP A Method For Preparing Oxycodone Hydrochloride Composition With Less Than 25Ppm Of 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102127086A PURDUE PHARMA LP Method For Preparing Pancodine Composition Containing Less Than 25 Ppm Of 14-Oxycodone
Mar, 2025

(2 years from now)

CN102887903A PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102127086B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102838607A PURDUE PHARMA LP Method For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm Of 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

CN102887903B PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2426132B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Compositions Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683A1 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683B8 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2316837B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151A4 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151B2 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2316837A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2319846A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2319846B1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2305683B1 PURDUE PHARMA LP Pharmaceutical Dosage Form Comprising Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP1730151A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Having Less Than 25 Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

EP2426132A1 PURDUE PHARMA LP Process For Preparing Oxycodone Hydrochloride Compositions Having Less Than 25Ppm 14-Hydroxycodeinone
Mar, 2025

(2 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, EXTENDED RELEASE;ORAL Prescription
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
20MG TABLET, EXTENDED RELEASE;ORAL